LYL797
Phase 1TerminatedDevelopment Stage
Triple Negative Breast Cancer
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
Mar 29, 2022 → Nov 27, 2024
About LYL797
LYL797 is a phase 1 stage product being developed by Lyell Immunopharma for Triple Negative Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05274451. Target conditions include Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer.
What happened to similar drugs?
1 of 20 similar drugs in Triple Negative Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05274451 | Phase 1 | Terminated |
Competing Products
20 competing products in Triple Negative Breast Cancer